Mary M. Gooley Hemophilia Center

Caring is in our blood

  • Location
  • Contact
  • Donate
1415 Portland Avenue Suite 500, Rochester, NY 14621
p. 585-922-5700  |  f. 585-922-5775
Mon-Fri: 8am-4:30pm  |  After hours 585-399-1717
  • About Us
    • The Center Today
    • Our History
    • Our Team
    • Board of Directors
  • What
    We Treat
    • Hemophilia
    • von Willebrand Disease
    • Rare Bleeding Disorders
    • Hemochromatosis/Iron Overload
    • Gaucher Disease
  • Our Care
    Model
    • Comprehensive Care Treatment
    • Research
  • Pharmacy
    Program
    • Pharmacy – Patients
    • Pharmacy – Payers
  • Programs &
    Services
    • Support & Education
    • Helpful Resources
    • Patient Assistance Programs
    • Insurance Counseling
    • Camps for Kids
    • Scholarship Opportunities
  • Event
    Calendar
  • Advocacy
You are here: Home > What We Treat > Gaucher Disease

Gaucher Disease

Gaucher's DiseaseGaucher (or Gaucher’s) Disease is caused by a hereditary deficiency of the enzyme glucocerebrosidase. The enzyme acts on the fatty acid glucosylceramide. When the enzyme is defective or deficient, glucosylceramide can accumulate in the spleen, liver, kidneys, lungs, brain and bone marrow.

Manifestations may include (often painless) enlarged spleen and liver, liver malfunction, skeletal disorders and bone lesions that may be painful, neurologic complications, swelling of lymph nodes and (occasionally) adjacent joints, distended abdomen, a brownish tint to the skin, anemia, low blood platelets and yellow fatty deposits on the white of the eye (sclera). Persons affected most seriously may also be more susceptible to infection.

Bone Cell with GauchersAround 1 in 100 people in the general U.S. population is a carrier for Type I Gaucher’s disease. The disease is caused by a recessive mutation in a gene located on chromosome 1 and affects both males and females. Among people of Ashkenazi Jewish descent, the rate of carriers is considerably higher, at roughly 1 in 15 people.

Some forms of Gaucher’s disease (including Type I) can be treated with enzyme replacement therapy (an IV therapy) to bolster the deficient or defective glucocerebrosidase. Enzyme replacement therapy has been shown to be effective when it is started before bone damage or other complications occur and is done regularly.

The disease is named after the French doctor Philippe Gaucher, who originally described it in the year 1882.

If you are of Ashkenazi descent, ask about testing. If you are on enzyme replacement therapy, keep your treatment appointments.

In This Section

  • About Us
    • The Center Today
    • Our History
    • Our Team
    • Board of Directors
  • What
    We Treat
    • Hemophilia
    • von Willebrand Disease
    • Rare Bleeding Disorders
    • Hemochromatosis/Iron Overload
    • Gaucher Disease
  • Our Care
    Model
    • Comprehensive Care Treatment
    • Research
  • Pharmacy
    Program
    • Pharmacy – Patients
    • Pharmacy – Payers
  • Programs &
    Services
    • Support & Education
    • Helpful Resources
    • Patient Assistance Programs
    • Insurance Counseling
    • Camps for Kids
    • Scholarship Opportunities
  • Event
    Calendar
  • Advocacy

How To Get Involved
Announcements
Announcements
Announcements
Announcements

Save the Date!

Stay Tuned!
Announcements

United Way Campaign 2023

Thank You!
Announcements

Important Health Insurance News!

Important News!

Contact

TEL 585-922-5700
FAX 585-922-5775
Mon-Fri: 8am-4:30pm
After hours 585-399-1717

Address

1415 Portland Avenue Suite 500
Rochester, NY 14621

Connect

Facebook Twitter YouTube
How to Get Involved
Donate
© 2023 Mary M. Gooley Hemophilia Center | Privacy Policy | HIPAA Privacy Notice | Compliance Policy | Patient Bill of Rights | Protections Against Surprise Medical Bills